Race Oncology (ASX:RAC) has announced the successful and safe combination dosing of the first patient with RC220 plus doxorubicin in its Phase 1 clinical trial in advanced solid tumour patients.
The patient was treated at the study’s lead trial site, Southside Cancer Care Centre in Sydney.
The company reported that no treatment-related dose-limiting adverse effects were observed.
Race Oncology Vice President of Medical, Dr Simon Fisher, said, “The initiation of this trial and the early safety observations are encouraging. We are partnering well with our Australian sites and working diligently to activate additional sites in Hong Kong and South Korea. We remain excited with the progress of RC220 in the clinic and its potential to offer an improved treatment option for the many patients at risk of cardiotoxicity related to doxorubicin therapy.”
Race’s Phase 1 solid tumour clinical trial is open-label and will be conducted across multiple sites in Australia, Hong Kong and South Korea. In stage 1 of the trial, ascending doses of RC220 will be used to determine the safety, tolerability, pharmacokinetics and maximum tolerated combined dose of RC220 in combination with doxorubicin in up to 33 patients.
After interim analysis of the data, the optimal dosage of RC220 in combination with doxorubicin will be assessed in an additional 20 patients in Stage 2 for further safety, tolerability, and preliminary cardioprotective and anticancer efficacy signals.